Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk

CVD-T2DM

Endocrine Society Guidelines App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/58913

Contents of this Issue

Navigation

Page 10 of 11

Contraindications Active liver disease Arterial bleeding Clinical Trial Results None completed Active liver disease Arterial bleeding Pregnant or nursing women or those desiring to be pregnant None completed Active liver disease Pregnant or nursing women or those desiring to be pregnant Active or chronic liver disease Pregnancy, lactation or desire to become pregnant None completed Significant dose-related reductions in systolic blood pressure (SBP), diastolic blood pressure (DBP) and LDL-C standard doses of atorvastatin and simvastatin (The Advicor Versus Other Cholesterol-Modulating Agents Trial of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) olesterolemic patients. Curr Med Res Opin. 2006;22(10):2041-2053.

Articles in this issue

Archives of this issue

view archives of Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk - CVD-T2DM